单鼻导管设计在高流速治疗中的效果:较低气体流量下疗效相当
本研究为随机交叉评估,纳入31例、完成26例高碳酸血症COPD且呼吸困难高于基线的患者,在门诊及住院重症监护场景接受高流速治疗。先用传统双鼻导管确定最有效流量,再随机使用新型双鼻导管或单鼻导管并重新滴定至最佳流量,记录RPD评分、生命体征、经皮二氧化碳分压及医患感知。传统、新型双鼻、单鼻导管缓解呼吸困难的中位流量分别为25、25、15 L/min;单鼻导管在显著更低流量下提供相当疗效(传统 vs 单鼻 P<0.0001,新型双鼻 vs 单鼻 P<0.0001)。作者认为单鼻导管用于高流速治疗值得进一步研究。
要点
- 单鼻导管缓解呼吸困难的中位流量为15 L/min(13-17 L/min),显著低于传统双鼻导管的25 L/min(20-30 L/min)和新型双鼻导管的25 L/min(19.1-30 L/min),P均<0.0001。
- 传统、新型双鼻、单鼻导管RPD较基线变化分别为-1(-1至0)、-1(-2至-1)、-1(-2至-1);新型双鼻和单鼻较传统比较差异有统计学意义(P=0.044和P=0.01)。
- 三种导管相比基线,生命体征和经皮二氧化碳分压变化相似。
- 31例入组、26例完成试验,研究对象为呼吸困难高于基线的高碳酸血症COPD患者。
- 作者结论:新导管设计提供相当的呼吸困难缓解,单鼻导管以显著更低流量提供相当疗效,其用于高流速治疗值得进一步研究。
适用人群与场景
- 高碳酸血症COPD且呼吸困难高于基线的患者。
- 研究场景为门诊和住院重症监护环境。
处置流程与药物剂量
- 先用现有高流速治疗传统双鼻导管确定最有效流量,再将患者随机分配至新型双鼻导管或单鼻导管并重新滴定至最佳流量。
- 每次治疗期间记录RPD评分、生命体征、经皮二氧化碳分压及临床医生/患者感知。
研究设计与关键结果
- 研究设计为随机交叉评估,入组31例,完成26例。
- 传统、新型双鼻、单鼻导管缓解呼吸困难的中位流量分别为25 L/min(20-30 L/min)、25 L/min(19.1-30 L/min)、15 L/min(13-17 L/min)。
- 传统、新型双鼻、单鼻导管RPD较基线变化分别为-1(-1至0)、-1(-2至-1)、-1(-2至-1)。
- 新型双鼻和单鼻导管RPD较基线变化与传统导管相比差异有统计学意义(P=0.044和P=0.01)。
- 三种导管相比基线,生命体征和经皮二氧化碳分压变化相似。
- 单鼻导管在显著更低流量下提供相当疗效:传统 vs 单鼻 P<0.0001,新型双鼻 vs 单鼻 P<0.0001。
证据类型、等级与局限
- 证据类型:随机交叉评估。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,新导管设计提供了相当的呼吸困难缓解;单鼻导管以显著更低流量提供相当疗效,其用于高流速治疗值得进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: High velocity therapy (HVT), a form of high-flow oxygen therapy, utilizing a small-bore nasal cannula has been widely used in acute care settings. A new dual-prong (newDP) cannula made using more comfortable material and a single-prong (SP) cannula were evaluated to compare comfort and functionality as measured by relief of dyspnea of patients with chronic obstructive pulmonary disease (COPD) receiving HVT therapy.
DESIGN: Randomized crossover evaluation.
SETTING: Outpatient and in patient critical care setting.
PATIENTS: Patients with hypercapnic COPD presenting with dyspnea above baseline.
INTERVENTIONS: HVT therapy was provided using an existing HVT dual-prong nasal cannula (traditional) to determine the most efficacious flow rate. Patients were then randomized to receive either the newDP cannula, or the SP cannula, and retitrated for optimal flow rate. During each session of therapy, Rated Perceived Dyspnea (RPD) scores, vital signs, transcutaneous carbon dioxide partial pressure (PTCco2) levels, and clinician/ patient perceptions were documented.
MEASUREMENTS AND MAIN RESULTS: Of 31 enrolled, 26 patients completed the trial. The median flow rate that relieved dyspnea for the traditional, newDP, and SP cannulas were 25 L/min (20-30 L/min), 25 L/min (19.1-30 L/min), and 15 L/min (13-17 L/min), respectively. The change in RPD from baseline for traditional, newDP, and SP were -1 (-1 to 0), -1 (-2 to -1), and -1 (-2 to -1). Change in RPD from baseline for newDP and SP compared with the traditional cannula was significantly different (p = 0.044 and p = 0.01, respectively). Changes in vital signs and PTCco2 were similar between the three cannula types compared with baseline. The SP cannula provided comparable therapeutic efficacy at significantly lower flow rates (traditional vs. SP; p < 0.0001 and newDP vs. SP; p < 0.0001).
CONCLUSIONS: The new cannula designs provided comparable relief of dyspnea. The single-prong cannula provided comparable efficacy at significantly lower flow rates (traditional vs. SP; p < 0.0001 and newDP vs. SP; p < 0.0001). The use of a single-prong cannula with HVT warrants further study.
参考来源
- Atwood C, Sethi J, Bergeski A, et al. Effect of Single-Prong Cannula Design With High Velocity Therapy: Comparable Efficacy at Lower Gas Flow Rates. Crit Care Explor. 2025. PMID: 39937568. doi:10.1097/CCE.0000000000001209
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。